,
10 tweets,
8 min read
Read on Twitter
News:
After 22y @MassGeneralNews @broadinstitute understanding risk & resistance to heart attack,
I am moving to new role as CEO @VerveTx - a biotech we have founded
to develop gene editing Rx that permanently reduce risk of coronary disease in adults
vervetx.com
After 22y @MassGeneralNews @broadinstitute understanding risk & resistance to heart attack,
I am moving to new role as CEO @VerveTx - a biotech we have founded
to develop gene editing Rx that permanently reduce risk of coronary disease in adults
vervetx.com
@VerveTx has been built to address one problem - heart attack
*the world’s leading killer
*is rising in prevalence worldwide
*present day, chronic care medicines and lifestyle recommendations not adequately changing that reality
vervetx.com/why-heart-dise…
*the world’s leading killer
*is rising in prevalence worldwide
*present day, chronic care medicines and lifestyle recommendations not adequately changing that reality
vervetx.com/why-heart-dise…
@VerveTx seeks to re-imagine the way we treat coronary disease.
Imagine: an injection, administered once in life, that safely confers enduring protection against coronary artery disease in adults
This is the therapy that we will build at @VerveTx
vervetx.com/approach/
Imagine: an injection, administered once in life, that safely confers enduring protection against coronary artery disease in adults
This is the therapy that we will build at @VerveTx
vervetx.com/approach/
What’s basis for vision?
Human genetic research -> 2 strong conclusions:
1. some people are born with protective mutations: healthy & resistant to heart attack
2. if carry variants that ⬇️ LDL and/or TRL lifelong, much less likely to get heart attack
vervetx.com/why-heart-dise…
Human genetic research -> 2 strong conclusions:
1. some people are born with protective mutations: healthy & resistant to heart attack
2. if carry variants that ⬇️ LDL and/or TRL lifelong, much less likely to get heart attack
vervetx.com/why-heart-dise…
We’ve assembled a team of leaders in the fields of
cardiovascular disease, gene editing, and drug development, and our early preclinical data are promising.
vervetx.com/about-us/
cardiovascular disease, gene editing, and drug development, and our early preclinical data are promising.
vervetx.com/about-us/
We are supported by:
*Series A funding $58.5M from leading biotech investors (@GVTeam Arch Venture Partners @FPrimeCapital & Biomatics Capital)
*Partnerships (Beam Therapeutics, Verily)
Ppl who are committed to @VerveTx mission to develop Rx that protects the world from CAD
*Series A funding $58.5M from leading biotech investors (@GVTeam Arch Venture Partners @FPrimeCapital & Biomatics Capital)
*Partnerships (Beam Therapeutics, Verily)
Ppl who are committed to @VerveTx mission to develop Rx that protects the world from CAD
Special thanks to Anthony Philippakis and @kyeshwant @GVTeam who have helped nurture @VerveTx from concept in 2016 to launch today
vervetx.com/about-us/
vervetx.com/about-us/
On a personal note, this transition is bittersweet
Grateful (🙏🏽) to (L) and (R)
Grateful (🙏🏽) to (L) and (R)
1980: traveled w/ brother on long journey from India to Pittsburgh
Intervening 39y: joy (family, deciphering genetics heart attack) & pain (lost brother @ age 42 to heart attack)
Now: excited to lead @VerveTx & develop new Rx that can protect families & world from heart attack
Intervening 39y: joy (family, deciphering genetics heart attack) & pain (lost brother @ age 42 to heart attack)
Now: excited to lead @VerveTx & develop new Rx that can protect families & world from heart attack
Join @VerveTx on our mission to protect the world from heart disease.
👇🏽positions open:
Lead scientist, Formulation and Delivery
Director, Preclinical Pharmacology
Associate Director/Manager, Program Alliance
apply at careers@vervetx.com
👇🏽positions open:
Lead scientist, Formulation and Delivery
Director, Preclinical Pharmacology
Associate Director/Manager, Program Alliance
apply at careers@vervetx.com
